Comparison of fibrinolytic and amidolytic methods for the measurement of streptokinase pharmacokinetics in patients with acute myocardial infarction

Fears, Robin; Ferres, H.; Glasgow, Eric; Greenwood, H.; Standring, R.

doi:10.1016/0268-9499(89)90016-7

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimates based on fibrin plate lysis assay in patients with acute myocardial infarction have demonstrated a half-life of approximately 37 minutes (Gemmill et al 1991;Kohler et al 1987) which is slightly longer than the 18 to 29 minutes based on other functional assays such as 125I-fibrin tubes or amidolytic assay of plasminogen activator activity in euglobulin fractions (Fears et al 1989;Martin 1982;Mentzer et al 1986). Estimates based on fibrin plate lysis assay in patients with acute myocardial infarction have demonstrated a half-life of approximately 37 minutes (Gemmill et al 1991;Kohler et al 1987) which is slightly longer than the 18 to 29 minutes based on other functional assays such as 125I-fibrin tubes or amidolytic assay of plasminogen activator activity in euglobulin fractions (Fears et al 1989;Martin 1982;Mentzer et al 1986).…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 95%

See 1 more Smart Citation

Streptokinase

Battershill¹,

Benfield²,

Goa³

1994

Drugs & Aging

View full text Add to dashboard Cite

Streptokinase has been administered to many thousands of elderly patients with acute myocardial infarction. Results of large, randomised trials provide convincing evidence that intravenous streptokinase confers a distinct survival benefit in this population subgroup following myocardial infarction. The placebo-controlled ISIS-2 study demonstrated a 5-week absolute mortality reduction of 38 per 1000 patients aged 60 to 69 years administered streptokinase, compared with only 16 per 1000 for patients aged less than 60 years. Combining streptokinase with aspirin further reduces mortality, as shown by a 5-week absolute mortality reduction of 70 per 1000 patients aged 60 to 69 years administered this regimen in the ISIS-2 trial. While ideally patients should receive streptokinase as soon as possible after symptom onset, late benefit has been observed in patients presenting up to 12 hours after pain onset, as is often the case with the elderly. Indeed, in patients treated > 6 hours after infarct in the GUSTO trial, streptokinase produced lower mortality results than accelerated recombinant tissue plasminogen activator (rt-PA). However, in contrast to the similar effects of streptokinase and conventionally administered rt-PA on overall survival demonstrated in previous large trials, the GUSTO study showed a lower mortality rate for accelerated rt-PA than for streptokinase in the elderly and in the total patient population. The most frequent adverse effects associated with streptokinase therapy are haemorrhagic complications, with an incidence of 0.4% for major bleeding (requiring transfusion) and 3.6% for minor bleeding among the total population in the GISSI-1 and ISIS-2 trials. An excess of stroke, particularly haemorrhagic stroke, occurring with rt-PA in GUSTO and other major mortality trials affirms the use of streptokinase as a suitable option in the elderly who are at increased risk of this complication. Significantly reduced values of end-systolic volume and regional wall motion index have been observed in elderly patients following streptokinase therapy. Overall, streptokinase and rt-PA seem to cause similar improvements in left ventricular function in this age group. Patency of occluded coronary arteries appears to be achieved in a high percentage of elderly patients following streptokinase therapy, based on a small sample. Thus, in view of the extensive clinical experience that now exists, intravenous streptokinase represents an appropriate alternative in elderly patients with acute myocardial infarction, and may be considered a first-line therapy in selected individuals, such as those with multiple risk factors for stroke or who present later than 6 hours after infarct.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Section: Pharmacokinetic Propertiesmentioning

confidence: 95%

“…Measurements of average peak plasma streptokinase activity have varied widely from 175 Ulml following streptokinase 1.5 million units in 12 patients (Fears et al 1989) to 257 U/ml after 0.25 million units and 560 U/ml after 0.5 million units, in 11 patients and 2 healthy volunteers ( fig. 3) [Grierson & Bjornsson 1987].…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%